Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Sequencing

NCT07106853 · tracked via the Priya Life Science China tracker

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Phase

Observational

Started

2025-09-16

Last updated

2026-09-17

Condition(s) studied

Genetic Disease

Study summary

This multicenter study aims to recruit a minimum of 1,600 pregnant women, encompassing individuals with varying levels of genetic risk. The study particularly focuses on cases with increased fetal nuchal translucency (NT ≥3.5 mm), additional ultrasound markers, and/or fetal structural anomalies. Peripheral blood samples of eligible participants will be collected for two state-of-the-art cfDNA tests based on coordinative allele-aware target enrichment sequencing (COATE-seq): (1) a targeted panel to screen for frequent chromosomal aneuploidies, microdeletions/duplications, and dominant single-gene conditions, and (2) comprehensive whole-exome cfDNA sequencing for aneuploidies, microdeletions/duplications, monogenic variants (both dominant and recessive variants), uniparental disomy, and hydatidiform moles. The results of both cfDNA tests will be compared with those from invasive or postnatal diagnostic testing. Pregnancy outcome will be followed up to six weeks postpartum. The primary goal is to determine the clinical validity of targeted and whole exome cfDNA analyses, assessed through sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) relative to diagnostic standards. Secondary goal is to assess efficacy across diverse genetic risk populations by analyzing detection rates of pathogenic variants associated with fetal indications. The clinical utility of cfDNA screening will also be evaluated by its impact on clinical management decisions, including follow-up diagnostic procedures or prenatal/perinatal interventions.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adult pregnant woman (≥18 years old) * Gestational age between 9+0 and 25+6 weeks * Singleton pregnancy * Pregnancy with indications for prenatal diagnosis due to: * Increased nuchal translucency (NT) ≥3.5 mm: capped at 25% of total subjects * Increased NT ≥3.5 mm AND presence of any other "soft marker" or structural anomaly: capped at 25% of total subjects * Presence of structural anomaly: at least 50% of total subjects * Agree to participate in the clinical study for being followed-up and accept at least one molecular diagnosis (diagnostic procedures performed on prenatal invasive specimens, product of conception, umbilical cord blood, or other specimens) and possible family member testing Exclusion Criteria: * Age under 18 years * Gestational age is less than 9+0 weeks or greater than 25+6 weeks * One parent or other family member has a known pathogenic variant linked to the fetal ultrasound finding(s) * Conditions affecting the accuracy of cfDNA assay (e.g., maternal malignancy during pregnancy, maternal allogeneic blood transfusion, organ transplantation, or cell therapy within the past year)

Primary outcome measure(s)

Determine the clinical validity of targeted and whole exome cfDNA analyses, assessed through sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) relative to diagnostic standards. — 18 months

Trial sites (2)

Facility	City	Region	Status
Women's Hospital School Of Medicine Zhejiang University	Hangzhou	Zhejiang	Recruiting
The Chinese University of Hong Kong	Hong Kong	Hong Kong	Recruiting

More Women's Hospital School Of Medicine Zhejiang University trials in China

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial Recruiting

Association of Gestational Cardiovascular Health With Pregnancy Outcomes Recruiting

A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China Recruiting

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer Starting soon

Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer Starting soon

Other trials for the same condition

Association Between Genetic Polymorphisms and Type 2 Asthma in Children Recruiting

Microfluidic Chip vs Density Gradient Centrifugation on the Euploidy Rate of Pre-implantation Genetic Testing Recruiting

Auditory Restoration and Outcomes After Gene Therapy and Cochlear Implantation: a PRospective Cohort Analysis (AURORA) Recruiting

Accurate Assessment and Intervention Research on Newborn Whole Genome Sequencing and Genetic Disease Risk Recruiting

Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07106853 on ClinicalTrials.gov ↗ ← All trials in China